Danske Bank A S boosted its holdings in Stryker Corporation (NYSE:SYK – Free Report) by 4.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 218,478 shares of the medical technology company’s stock after purchasing an additional 9,421 shares during the period. Danske Bank A S’s holdings in Stryker were worth $60,167,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Gables Capital Management Inc. bought a new stake in Stryker during the 2nd quarter worth about $25,000. Kilter Group LLC acquired a new position in shares of Stryker during the 2nd quarter worth about $25,000. Cornerstone Financial Management LLC boosted its stake in shares of Stryker by 66.0% during the 2nd quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock worth $25,000 after buying an additional 31 shares during the last quarter. Highland Investment Advisors LLC bought a new position in shares of Stryker in the 2nd quarter valued at about $25,000. Finally, Compass Financial Management LLC bought a new position in shares of Stryker in the 2nd quarter valued at about $27,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity at Stryker
In related news, Director Ronda Stryker sold 550,000 shares of Stryker stock in a transaction dated Friday, November 6th. The stock was sold at an average price of $325.32, for a total transaction of $178,926,000.00. Following the completion of the transaction, the director owned 1,701,375 shares in the company, valued at approximately $553,491,315. This trade represents a 24.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Debra King sold 826 shares of Stryker stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the transaction, the insider owned 6,210 shares of the company’s stock, valued at $2,088,423. The trade was a 11.74% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 901,267 shares of company stock worth $297,123,701. Insiders own 4.60% of the company’s stock.
Wall Street Analysts Forecast Growth
SYK has been the topic of a number of recent research reports. JPMorgan Chase & Co. lowered their target price on Stryker from $350.00 to $340.00 and set an “overweight” rating on the stock in a research report on Friday, October 30th. Leerink Partners reduced their price target on Stryker from $403.00 to $353.00 and set an “outperform” rating for the company in a research report on Friday, October 9th. BMO Capital Markets restated an “outperform” rating and issued a $309.00 price target (down from $317.00) on shares of Stryker in a research note on Friday, October 30th. Truist Financial reaffirmed a “hold” rating and set a $305.00 price target (down from $310.00) on shares of Stryker in a research report on Monday, November 2nd. Finally, Needham & Company LLC dropped their price objective on Stryker from $418.00 to $359.00 and set a “buy” rating on the stock in a research note on Friday, October 30th. Twenty-one equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat, Stryker has a consensus rating of “Moderate Buy” and an average price target of $342.19.
Read Our Latest Analysis on Stryker
Stryker Stock Performance
Shares of SYK stock opened at $309.05 on Monday. The company has a fifty day moving average price of $292.30 and a two-hundred day moving average price of $322.60. Stryker Corporation has a one year low of $267.00 and a one year high of $389.33. The stock has a market cap of $117.65 billion, a P/E ratio of 32.91, a P/E/G ratio of 2.13 and a beta of 0.78. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.18 and a quick ratio of 1.30.
Stryker (NYSE:SYK – Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The medical technology company reported $3.52 earnings per share for the quarter, missing the consensus estimate of $3.55 by ($0.03). The firm had revenue of $6.52 billion for the quarter, compared to analyst estimates of $6.62 billion. Stryker had a return on equity of 23.74% and a net margin of 13.78%. The firm’s revenue for the quarter was up 7.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.19 earnings per share. As a group, equities analysts predict that Stryker Corporation will post 14.85 EPS for the current year.
About Stryker
Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings. The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.
Recommended Stories
- Five stocks we like better than Stryker
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
